Results 171 to 180 of about 27,503 (257)

Dipeptidyl peptidase-4 inhibitor linagliptin improves fibrosis, apoptosis, and cardiac function in a large animal model of chronic myocardial ischemia. [PDF]

J Pharmacol Exp Ther
Harris DD, Stone C, Broadwin M, Kanuparthy M, Sabe SA, Nho JW, Hamze J, Abid MR, Sellke FW.   +8 more
europepmc   +1 more source

Dipeptidyl peptidase‐4 inhibitor approaches

Journal of Diabetes, 2016
openaire   +1 more source

SGLT‐2 Inhibitors are Associated With a Lower Risk of Multiple Myeloma

European Journal of Haematology, Volume 117, Issue 5, Page 1347-1357, November 2026.
ABSTRACT Aims We aimed to investigate drug response of sodium‐glucose transport protein‐2 inhibitors (SGLT2i) in multiple myeloma (MM), as SGLT2i have potential favorable effects on conditions related to MM. Methods We conducted a pharmacoepidemiologic study with a US nationwide health insurance claim data using Cox models to investigate the ...
Enze Liu, Anna Sun, Yuedi Yang, Jing Xu, Attaya Suvannasankha, Brian A. Walker, Pengyue Zhang   +6 more
wiley   +1 more source

Association between the body mass index and risk of cardiovascular events in sodium-glucose cotransporter 2 inhibitor users compared with dipeptidyl-peptidase 4 inhibitor users: A nationwide cohort study in Korea. [PDF]

Diabetes Obes Metab
Ko HY, Jung K, Cho Y, Bea S, Bae JH, Cho YM, Rhee SY, Shin JY.   +7 more
europepmc   +1 more source

Immune Consequences of Metabolic Syndrome and Its Treatment: A Cytokine Perspective

Immunology, Volume 179, Issue 3, Page 390-405, November 2026.
Peripheral blood mononuclear cells (PBMCs) from individuals with metabolic syndrome (MetS) who were not using glucose‐and/or lipid lowering medication (GLLM) exhibited a broader cytokine production profile after in vitro antigen‐specific stimulation than PBMCs from individuals with MetS using such medications and from healthy donors.
Isabela Ghetti Macedo Isaac, Carolina do Prado Servian, Fernanda de Oliveira Feitosa de Castro, João Lucas Lima Calandrini de Azevedo, Ronaldo Moraes Preto, Miriam Leandro Dorta, Daniela Espíndola Antunes, Simone Gonçalves Fonseca   +7 more
wiley   +1 more source

Rurality is associated with lower likelihood of dipeptidyl peptidase 4 inhibitor use for treatment intensification. [PDF]

Explor Res Clin Soc Pharm
Nagy DK, Bresee LC, Eurich DT, Simpson SH.   +3 more
europepmc   +1 more source

GLP‐1 Receptor Agonists and Weight Loss: A Critical Review of Mechanisms

Obesity Reviews, Volume 27, Issue 11, November 2026.
ABSTRACT GLP‐1 receptor agonist medications have the potential to promote marked weight loss, but maximal and sustained benefit may be compromised by poor compliance and cessation of use. Development of next‐generation medications that address current obstacles to effective use and development of effective adjunct treatments will benefit from better ...
Giorgia Rutigliani, Tzu‐Wen L. Cross, Erica de Jong, Emily S. Glover, Ivan D. Mendoza, Mojisola Adisa, Keigo Tomoo, Xinyi Zhou, Richard D. Mattes   +8 more
wiley   +1 more source

A case of immunoglobulin G4-related kidney disease manifesting after dipeptidyl peptidase-4 inhibitor treatment. [PDF]

CEN Case Rep
Ubara Y, Takeuchi T, Hasegawa E, Sekine A, Inoue N, Tanaka K, Mizuno H, Oba Y, Yamanouchi M, Suwabe T, Kono K, Kinowaki K, Ohashi K, Yamaguchi Y, Sawa N, Wada T.   +15 more
europepmc   +1 more source

Hitting Coronaviruses Where It Hurts: Antiviral Strategies Targeting Viral Proteins

ChemMedChem, Volume 21, Issue 19, 14 October 2026.
Viral proteins represent key vulnerabilities in human coronaviruses (HCoVs). This review outlines inhibitors targeting spike (S), main protease (Mpro), papain‐like protease (PLpro), and RNA‐dependent RNA polymerase (RdRp), mapping chemically diverse strategies that disrupt entry and replication, and provides an integrated view of current candidates ...
Álvaro de la Cruz‐Potenciano, Miguel Maldonado, María‐José Camarasa, Sonia de Castro   +3 more
wiley   +1 more source